Pat, I share your views on this. We certainly hope this is for real, but the details seem sketchy.

He doesn't know where the biopsy was taken from? Who is this Dr. Riordan fellow? Where did he come from?

Matthew's Dad.

Views: 84

Comment

You need to be a member of PPMD Community to add comments!

Join PPMD Community


Staff
Comment by Pat Furlong on November 15, 2009 at 9:16am
Hi Martin, Dr. Riordan knew Ryan and his family before moving to Costa Rica. The other two families had some relationship with him or were connected (friend of a friend). Dr. Riordan is exploring MSCs and potential application to a number of diseases. Biopsy and testing was not done in Costa Rica, so Dr. Riordan is going on Athena's results. Probably would be a good idea to release Athena's report and tissue specimens to another lab for testing. Dr. Riordan has a paper in press and is clearly interested in conducting clinical trials. You will see below his description of improved strength. I think it would be important to understand what strength testing methods were used, who performed the testing and what the 2.5-4 means in terms of function. And regulatory agencies will not accept 'stable trunk' and 'less respiratory infections". The only way to nail this down is collaborations with research and clinical trials. I have forwarded the paper onto Gillian Butler-Browne and others.

" Thus, a pre-transplantation strength of 2-2.5/5 in
the neck, shoulder, upper, and lower extremities began to improve after each of the two
stem cell administrations, and reached a final 4/5 level 1 month after second
transplantation treatment. The increments in muscle strength after the two stem cell
administration appeared to be additive, with most benefit recorded after the second.
Upper extremity improvement in strength evolved from the incapacity to lift against
gravity before the transplantation towards the ability to lift 2 lbs weights after the
procedure. Trunk balance and strength were also markedly improved. The patient gained
20 lbs, along with an increased general activity level. The frequency of respiratory
infections decreased from 3-4/year before stem cell therapy to none. The inspiratory
effort improved from -32 to -40 cm H20. A muscle biopsy taken in January 2009
demonstrated normal (>50%, normal = 50-100% expression of normal-molecular size)
levels of muscular dystrophin. The improvement in muscular strength, clinical respiratory
function, and general level of activity are maintained to date."

Need help using this community site? Visit Ning's Help Page.

Members

Events

© 2019   Created by PPMD.   Powered by

Badges  |  Report an Issue  |  Privacy Policy  |  Terms of Service